A review and meta-analysis of utility values for lung cancer

Medical Decision Making

Volumn 30, Issue 6, 2010, Pages 685-693

  Sturza, Julie ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

cost utility analysis; population based studies; randomized trial methodology; risk stratification; scale development validation

Indexed keywords

COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; NATIONAL HEALTH SERVICE; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL; UNITED KINGDOM;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; RISK ASSESSMENT; STATE MEDICINE;

EID: 78650804680     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10369004     Document Type: Article

References (63)

1. Center for Disease Control and Prevention. Lung cancer: statistics. Available from: URL: http://www.cdc.gov/cancer/lung/statistics/[needaccessdate?]
2. Center for Disease Control and Prevention. Lung cancer: cost of lung cancer. Available from: URL: http://www.cdc.gov/cancer/lung/statistics/cost. htm[needaccessdate?]
3. Alberg AJ, Brock MV, Samet JM Epidemiology of Lung Cancer: Looking to the Future. J Clin Oncol. 2005 ; 23 (14). 3175-85.
4. Bonner MR, Lee WJ, Sandler DP, Hoppin JA, Dosemeci M., Alavanja MC Occupational exposure to carbofuran and the incidence of cancer in the Agricultural Health Study. Environ Health Perspect. 2005 ; 113 (3). 285-9.
5. National Cancer Institute. What you need to know about lung cancer. Available from: URL: http://www.nci.nih.gov/cancertopics/wyntk/lung/ allpages[needaccessdate?]
6. Pershagen G. The carcinogenicity of arsenic. Environ Health Perspect. 1981 ; 40: 93-100.
7. Ward E. Overview of preventable industrial causes of occupational cancer. Environ Health Perspect. 1995 ; 103 (Supplement 8). 197-203.
8. Mastrangelo G., Fadda E., Marzia V. Polycyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect. 1996 ; 104 (11). 1166-70.
9. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM Outcomes and cost-effectiveness of alternative staging strategies for non- small-cell lung cancer. J Clin Oncol. 2002 ; 20 (1). 263-73.
10. Ferguson MK Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg. 2003 ; 126 (6). 1935-42.
11. Lee JJ, Bekele BN, Zhou X., Cantor SB, Komaki R., Lee JS Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol. 2006 ; 24 (22). 3597-603.
12. Brundage MD, Groome PA, Feldman-Stewart D., Davidson JR, Mackillop WJ Decision analysis in locally advanced non-small- cell lung cancer: is it useful ? J Clin Oncol. 1997 ; 15 (3). 873-83.
13. Tabberer M., Stamuli E., Walker M., Summerhayes M., Lees M. Utilities associated with non-small cell lung cancer (NSCLC): a community study. Value Health. 2007.
14. Manser RL, Wright G., Byrnes G., Hart D., Conron M., Carter R., et al. Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and nonperable lung cancer. Lung Cancer. 2006 ; 53: 217-29.
15. Gabriel SE, Kneeland TS, Melton LJ Health-related quality of life in economic evaluations for osteoporosis: whose values should we use ? Med Decis Making. 1999 ; 19: 141-8.
16. Fryback DG, Lawrence WF, Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making. 1997 ; 17 (3). 276-84.
17. King JT, Styn MA, Tsevat J., Roberts MS "Perfect health" versus "disease free": the impact of anchor point choice on the measurement of preferences and the calculation of disease-specific disutilities. Med Decis Making. 2003 ; 23 (3). 212-25.
18. King JT, Tsevat J., Roberts MS Impact of the scale upper anchor on health state preferences. Med Decis Making. 2009 ; 29 (2). 257-66.
19. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC Preferences for health outcomes. Comparison of assessment methods. Med Decis Making. 1984 ; 4 (3). 315-29.
20. Stiggelbout AM, Eijkemans MJ, Kiebert GM, Kievit J., Leer JW, De Haes HJ The 'utility' of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off? Int J Technol Assess Health Care. 1996 ; 12 (2). 291-8.
21. Stiggelbout AM, Kiebert GM, Kievit J., Leer JW, Stoter G., De Haes HJ Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making. 1994 ; 14 (1). 82-90.
22. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol. 1992 ; 45 (5). 505-12.
23. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ Whose utilities for decision analysis ? Med Decis Making. 1990 ; 10 (1). 58-67.
24. Polsky D., Willke RJ, Scott K., Schulman KA, Glick HA A comparison of scoring weights for the EuroQol derived from patients and the general public. Health Econ. 2001 ; 10 (1). 27-37.
25. Sackett DL, Torrance GW The utility of different health states as perceived by the general public. J Chronic Dis. 1978 ; 31: 697-704.
26. Tengs TO, Lin TH A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002 ; 22: 475-81.
27. Brown GC, Brown MM, Sharma S. Differences between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol. 2000 ; 35 (3). 127-33.
28. Bremner KE, Chong Caky, Tomlinson G., Alibhai SMH, Krahn MD A review and meta-analysis of prostate cancer utilities. Med Decis Making. 2007 ; 27: 288-98.
29. Tengs TO, Lin TH A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003 ; 21 (3). 191-200.
30. Dijkers M. Quality of life after spinal cord injury: a meta analysis of the effects of disablement components. Spinal Cord. 1997 ; 35: 829-40.
31. Cheng AK, Niparko JK Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999 ; 125 (11). 1214-8.
32. Cameron JI, Whiteside C., Katz J., Devins GM Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis. 2000 ; 35 (4). 629-37.
33. National Health Service. Economic Evaluation Database. Available from: URL: http://www.crd.york.ac.uk/crdweb/[needaccessdate?]
34. Tufts Center for the Evaluation of Value 92(16): 1321-9.
35. Cykert S., Joines JD, Kissling G., Hansen CJ Racial differences in patients' perceptions of debilitated health states. J Gen Intern Med. 1999 ; 14: 217-22.
36. Cykert S., Kissling G., Hansen CJ Patient preferences regarding possible outcomes of lung resection: what outcomes should preoperative evaluations target ? Chest. 2000 ; 117 (6). 1551-9.
37. Cykert S., Phifer N. Surgical decisions for early stage, non- small cell lung cancer: which racially sensitive perceptions of cancer are likely to explain racial variation in surgery ? Med Decis Making. 2003 ; 23: 167-76.
38. Dooms DA, Lievens YN, Vansteenkiste JF Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J. 2006 ; 27: 895-901.
39. Goodwin PJ, Feld R., Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988 ; 6 (10). 1537-47.
40. Kennedy W., Reinharz D., Tessier G., Contandriopoulos A-P., Trabut I., Champagne F., et al. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. Pharmacoeconomics. 1995 ; 8 (4). 316-23.
41. Ko CY, Maggard M., Livingston EH Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res. 2003 ; 114: 1-5.
42. Magnione CM, Goldman L., Orav J., Marcantonio ER, Pedan A., Ludwig LE, et al. Health-related quality of life after elective surgery: measurement of longitudinal changes. J Gen Intern Med. 1997 ; 12: 686-97.
43. Manser R., Dalton A., Carter R., Byrnes G., Elwood M., Campbell DA Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computer tomography) in the Australian setting. Lung Cancer. 2005 ; 48: 171-85.
44. Papatheofanis FJ Utility evaluations for Markov states of lung cancer for PET-based disease management. Q J Nucl Med. 2000 ; 44: 186-90.
45. Raab S., Hornberger J. The effect of a patient's risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions. Chest. 1997 ; 111: 1583-90.
46. Schaafsma J., Coy P. Response of global quality of life to high- dose palliative radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000 ; 47 (3). 691-701.
47. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Chevalier TL Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol. 1995 ; 13 (9). 2166-73.
48. Trippoli S., Vaiani M., Lucioni C., Messori A., Pharmacoeconomics Q-o-lSGotMPi. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics. 2001 ; 19 (8). 855-63.
49. van den Hout WB, Kramer Gwpm, Noordijk EM, Leer JWH. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2006 ; 98 (24). 1786-94.
50. Yabroff KR, McNeel TS, Waldron WR, Davis WW, Brown ML, Clauser S., et al. Health limitations and quality of life associated with cancer and other chronic diseases by phase of care. Med Care. 2007 ; 45 (7). 629-37.
51. Petitti DB Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 2nd ed. New York: Oxford University Press ; 2000.
52. Raudenbush SW, Bryk AS Hierarchical Linear Models: Applications and Data Analysis Methods. 2 nd ed. Thousand Oaks: Sage Publications ; 2002.
53. Singer JD Using SAS Proc MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat. 1998 ; 24 (4). 323-55.
54. Grady D. Studies Lead to Big Changes in Lung Cancer Treatments. NY Times. 23 June 2005.
55. Ciombor KK, Rocha Lima CM Management of small cell lung cancer. Curr Treat Options Oncol. 2006 ; 7 (1). 59-68.
56. Quan AL, Videtic GM, Suh JH Brain metastases in small cell lung cancer. Oncology (Williston Park). 2004 ; 18 (8). 961-72.
57. Institute of Medicine of the National Academies. Valuing Health for Regulatory Cost-Effectiveness Analysis. Washington, DC: The National Academies Press ; 2006.
58. Heo S., Moser D., Widener J. Gender differences in the effects of physical and emotional symptoms on health-related quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2007 ; 6 (2). 146-52.
59. Huguet N., Kaplan MS, Feeny D. Socioeconomic status and health-related quality of life among elderly people: Results from the Joint Canada/United States Survey of Health. Soc Sci Med. 2008 ; 66 (4). 803-10.
60. Jiang Y., Hesser JE Associations between health-related quality of life and demographics and health risks. Results from Rhode Island's 2002 behavioral risk factor survey. Health Qual Life Outcomes. 2006 ; 4.
61. Liu H., Feurer I., Dwyer K., Speroff T., Shaffer D., Wright Pin-son C. The effects of gender and age on health-related quality of life following kidney transplantation. J Clin Nurs. 2008 ; 17 (1). 82-9.
62. Riegel B., Moser DK, Rayens MK, Carlson B., Pressler SJ, Shively M., et al. Ethnic differences in quality of life in persons with heart failure. J Card Fail. 2008 ; 14 (1). 41-7.
63. Riegel B., Moser DK, Rayens MK, Carlson B., Pressler SJ, Shively M., et al. Ethnic differences in quality of life in persons with